Full Press Release Details
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team will present and participate in the following upcoming investor conferences:
Craig-Hallum Biotech Catalyst Conference
• Virtual fireside chat at 10:00 a.m. ET and virtual 1x1 investor meetings on Thursday, October 22, 2026
Guggenheim Securities 3 rd Annual Healthcare Innovation Conference
• Fireside chat at 1:00 p.m. ET and 1x1 investor meetings on Monday, November 9, 2026, in Boston, MA
Wolfe Research Healthcare Conference
• 1x1 investor meetings on Tuesday, November 10, 2026, in New York, NY
Stifel Healthcare Conference
• Fireside chat at 9:20 a.m. ET and 1x1 investor meetings on Thursday, November 12, 2026, in New York, NY
Webcasts for the fireside chats will be available on the “Investors” section under the “ Events ” page of the Company’s website at https://ir.lbpharma.us/, where a replay of the webcasts will be archived.
About LB Pharmaceuticals LB Pharmaceuticals is a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.